Table 1.
Clinical characteristics of the study.
| Variables | Total (n=40) |
TG (<1.7) | TG (≥1.7) | p |
|---|---|---|---|---|
| n=18 | n=22 | |||
| N (Female/Male) | 20/20 | 10/8 | 10/12 | 0.53 |
| Age (years) | 60.6 ± 1.13 | 59.8 ± 1.04 | 61.3 ± 1.24 | 0.69 |
| Weight (kg) | 95.5 ± 2.91 | 90.1 ± 3.83 | 100.9 ± 4.00 | 0.06 |
| Height (cm) | 170.9 ± 4.5 | 169.7 ± 5.4 | 170.9 ± 5.2 | 0.72 |
| BMI (kg/m2) | 33.0 ± 1.07 | 30.7 ± 1.12 | 35.0 ± 1.65 | 0.04 |
| Diabetic Complications, N (%) | ||||
| CAD | 8 (20) | 5 (28) | 3 (14) | 0.13 |
| Stroke | 1 (3) | 1 (6) | 0 (0) | – |
| PAD | 3 (8) | 1 (6) | 2 (9) | 0.86 |
| Diabetic nephropathy | 8 (20) | 2 (11) | 6 (27) | 0.17 |
| Diabetic neuropathy | 2 (5) | 1 (6) | 1 (5) | 0.73 |
| Diabetic retinopathy | 3 (7) | 1 (6) | 2 (9) | 0.49 |
| Diabetic foot syndrome | 1 (3) | 0 (0) | 1 (5) | – |
| Hepatic and pancreatic, N (%) | ||||
| Liver cirrhosis | 8 (20) | 4 (22) | 4 (18) | 0.95 |
| Chronic pancreatitis | 2 (5) | 1(6) | 1 (5) | - |
| Medications, N (%) | ||||
| Metformin | 23 (58) | 11 (61) | 12 (55) | 0.83 |
| DPP-IV-Inhibitor | 12 (30) | 6 (33) | 6 (27) | 0.68 |
| SGLT-2-Inhibitor | 7 (18) | 4 (22) | 3 (14) | 0.77 |
| Sulfonylurea | 1(3) | 1(6) | 0 (0) | – |
| Acarbse | 0 (0) | 0 (0) | 0 (0) | – |
| Glitazone | 0 (0) | 0 (0) | 0 (0) | – |
| GLP-1-Analoga | 4 (10) | 1 (6) | 3 (14) | 0.75 |
| Insulin | 20 (50) | 8 (44) | 12 (55) | 0.53 |
| Statin | 11 (28) | 6 (33) | 5 (23) | 0.70 |
| Fibrate | 0 (0) | 0 (0) | 0 (0) | – |
| Ezetimib | 3 (8) | 2 (11) | 1 (5) | 0.86 |
| Evolocumab | 1 (3) | 0 (0) | 1 (5) | – |
| ACE-Hemmer | 6 (15) | 4 (22) | 2 (9) | 0.48 |
| AT1-Receptor-Antagonist | 16 (40) | 7 (39) | 9 (41) | 0.90 |
| Ca-Channel-Blocker | 7 (18) | 3 (17) | 4 (18.2) | 0.77 |
| Beta-Blocker | 13 (33) | 4 (22) | 9 (41) | 0.21 |
| Diuretics | 11 (28) | 5 (28) | 5 (23) | 0.75 |
| ASS | 17 (43) | 11 (61) | 6 (27) | 0.03 |
Data are presented as mean ± SEM and number (percentage); p values are based on t-test or Chi-square test, and p < 0.05 was considered statistically significant; TG, triglyceride; BMI, body mass index; CAD, coronary artery disease; PAD, peripheral artery disease; ASS, aspirin; ‘-’: missing data.